EA202192305A1 - Новая рекомбинантная диаминоксидаза и её применение для лечения заболеваний, характеризующихся избытком гистамина - Google Patents

Новая рекомбинантная диаминоксидаза и её применение для лечения заболеваний, характеризующихся избытком гистамина

Info

Publication number
EA202192305A1
EA202192305A1 EA202192305A EA202192305A EA202192305A1 EA 202192305 A1 EA202192305 A1 EA 202192305A1 EA 202192305 A EA202192305 A EA 202192305A EA 202192305 A EA202192305 A EA 202192305A EA 202192305 A1 EA202192305 A1 EA 202192305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
histamine
dao
excess
diamine oxidase
Prior art date
Application number
EA202192305A
Other languages
English (en)
Inventor
Томас Бём
Бернд Йилма
Николь Борт
Элизабет Глудовац
Original Assignee
Медицинише Универзитэт Вин
Универзитэт Фюр Боденкультур Вин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медицинише Универзитэт Вин, Универзитэт Фюр Боденкультур Вин filed Critical Медицинише Универзитэт Вин
Publication of EA202192305A1 publication Critical patent/EA202192305A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03022—Diamine oxidase (1.4.3.22)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Evolutionary Biology (AREA)
  • Library & Information Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Изобретение касается рекомбинантной диаминоксидазы (DAO) человека с пониженным сродством связывания с гликозаминогликанами, причем такая DAO содержит по меньшей мере одну модификацию аминокислоты в домене связывания гликозаминогликанов (GAG). Настоящее изобретение также касается применения DAO при лечении заболеваний, связанных с избытком гистамина, в частности, при лечении хронических аллергических заболеваний, более конкретно при лечении анафилаксии, анафилактического шока, хронической крапивницы, острой крапивницы, астмы, сенной лихорадки, аллергического ринита, аллергического конъюнктивита, отравления гистамином, головной боли, атопического дерматита, воспалительных заболеваний, мастоцитоза, синдрома активации тучных клеток (MCAS), преэклампсии, гиперемезиса беременных, преждевременных родов, пептических язв, кислотного рефлюкса, зуда и сепсиса.
EA202192305A 2019-02-19 2020-02-18 Новая рекомбинантная диаминоксидаза и её применение для лечения заболеваний, характеризующихся избытком гистамина EA202192305A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157932 2019-02-19
PCT/EP2020/054197 WO2020169577A1 (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Publications (1)

Publication Number Publication Date
EA202192305A1 true EA202192305A1 (ru) 2021-12-08

Family

ID=65493995

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192305A EA202192305A1 (ru) 2019-02-19 2020-02-18 Новая рекомбинантная диаминоксидаза и её применение для лечения заболеваний, характеризующихся избытком гистамина

Country Status (13)

Country Link
US (1) US20220145269A1 (ru)
EP (1) EP3927817A1 (ru)
JP (1) JP2022520862A (ru)
KR (1) KR20210132650A (ru)
CN (1) CN113785052A (ru)
AU (1) AU2020225319A1 (ru)
BR (1) BR112021015865A2 (ru)
CA (1) CA3130751A1 (ru)
EA (1) EA202192305A1 (ru)
IL (1) IL285452A (ru)
MX (1) MX2021010050A (ru)
SG (1) SG11202107659SA (ru)
WO (1) WO2020169577A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3191387A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2023235897A2 (en) * 2022-06-03 2023-12-07 Oyster Point Pharma. Inc. Aav vector encoding diamine oxidase and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317067B1 (it) 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
CA2536016C (en) * 2002-08-16 2017-01-10 Paul L. Deangelis Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
AT502098B8 (de) 2004-07-07 2007-06-15 Albert Dr Missbichler Diaminooxidase-hältige zusammensetzung
US20130195830A1 (en) 2010-09-02 2013-08-01 Debreceni Egyetem Perorally applicable preparation containing histaminase of vegetable origin, resistant to pepsin and trypsin and a process for producing it
WO2023122254A2 (en) * 2021-12-22 2023-06-29 The Board Of Trustees Of The Leland Stanford Junior University Methods to elicit desire to mate and mating behavior

Also Published As

Publication number Publication date
IL285452A (en) 2021-09-30
CN113785052A (zh) 2021-12-10
MX2021010050A (es) 2021-09-21
JP2022520862A (ja) 2022-04-01
KR20210132650A (ko) 2021-11-04
US20220145269A1 (en) 2022-05-12
CA3130751A1 (en) 2020-08-27
BR112021015865A2 (pt) 2021-10-05
EP3927817A1 (en) 2021-12-29
SG11202107659SA (en) 2021-09-29
AU2020225319A1 (en) 2021-10-14
WO2020169577A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
EA202192305A1 (ru) Новая рекомбинантная диаминоксидаза и её применение для лечения заболеваний, характеризующихся избытком гистамина
Aluru et al. Lacrimal proline rich 4 (LPRR4) protein in the tear fluid is a potential biomarker of dry eye syndrome
EA201491827A1 (ru) Антитела против hla-b*27 и их применение
WO2014164959A3 (en) Anti-il-33 antibodies and uses thereof
MX365985B (es) Antagonistas de il-6 para aumentar la albumina y/o disminuir la crp.
NO20082942L (no) Ligander som binder IL-4 og/eller IL-13
NO20070153L (no) Loselig zcytorl4, anti-zcytorl4-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
BR112012007555A2 (pt) biomarcadores para prever a sensibilidade e resposta de doenças mediadas por quinase de proteína ck2 a inibidores de ck2
NO20072602L (no) Anti-IL-22RA-antistoffer og bindingspartnere og fremgangsmater for anvendelse ved inflammasjon
NZ630183A (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
MX344592B (es) Metodo para eliminar extracorporalmente de la sangre un microbio patogeno, una celula inflamatoria o una proteina inflamatoria.
MX2022014422A (es) Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos.
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
DK2185937T4 (da) Fremgangsmåde til at bestemme sepsis hos mennesker
WO2017208174A3 (en) Methods of treating disease with pfkfb3 inhibitors
Tehrani et al. Immunochemical characterization of Amaranthus retroflexus pollen extract: extensive cross-reactive allergenic components among the four species of Amaranthaceae/Chenopodiaceae
EA201100653A1 (ru) Лиганды, связывающиеся с интерлейкином-13 (il-13)
NO20052714D0 (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
EA201991283A1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости
WO2016145362A3 (en) Inhibitors of dek protein and related methods
MX2021015553A (es) Inhibidores de arginasa novedosos.
ZA202203367B (en) Treatment of menstrual cycle-induced symptoms
MX2022013007A (es) Eclitasertib para el uso en el tratamiento de afecciones que implican una respuesta hiperinflamatoria sistemica.
MX2022011692A (es) Tecnologias para prevenir o tratar infecciones.